Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

Journal of Neurosurgery

Volumn 95, Issue 3, 2001, Pages 472-479

  Nagane, M ^a   Narita, Y ^a   Mishima, K ^a   Levitzki, A ^a   Burgess, A W ^a   Cavenee, W K ^a   Su Huang, H J ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

Combined drug therapy; Drug resistance; Epidermal growth factor receptor; Glioblastoma multiforme; Mutant receptor; Tyrosine kinase inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; XENOGRAFT;

EID: 0034865816     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2001.95.3.0472     Document Type: Article

References (37)

1. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor
2. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
3. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
4. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
5. Brain tumor working group report on the 9th international conference on brain tumor research and therapy
6. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
7. Role of oncogenes in resistance and killing by cancer therapeutic agents
8. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
9. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
10. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
11. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
12. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
13. Therapeutic effects of local delivery of dexamethasone on experimental brain tumors and peritumoral brain edema
14. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation
15. Protein tyrosine kinase inhibitors as novel therapeutic agents
16. Tyrosine kinase inhibition: An approach to drug development
17. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
18. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
19. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
20. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor
21. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors
22. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
23. Advances in the molecular genetics of gliomas
24. Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma
25. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of BcI-XL and caspase-3-1ike proteases
26. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines
27. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
28. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
29. Epidermal-growth-factor-dependent activation of the src-family kinases
30. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
31. Molecular pathogenesis of malignant gliomas
32. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
33. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
34. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
35. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behavior in human glioblastoma
36. Function of aberrant EGFR in malignant gliomas
37. The class III variant of the epidermal growth factor receptor (EGFRvlII): Characterization and utilization as an immunotherapeutic target